Heart failure (HF) has a major impact on health-related quality of life (HQoL). The aim was to evaluate whether heart rate (HR) reduction with ivabradine can translate into increased HQoL in parallel to a reduction of primary outcomes in SHIFT.
Introduction
Heart failure (HF) is common and disabling and has major impact on health-related quality of life (HQoL). 1 In addition, patients with HF have a significantly lower HQoL compared with patients with other chronic conditions and impaired HQoL is increasingly being associated with poor outcome in terms of mortality and major morbidity. 2, 3 Health-related quality of life refers to the subjective perception of health, i.e. the impact of disease and treatment on health status (symptoms, daily functioning, and subjective well-being). 4 Therefore, HQoL evaluations are particularly important in a chronic, disabling condition, such as HF, because the primary goals of treatment include relief of symptoms, optimization of daily functions of life, and minimization of the impact of disease on well-being. In spite of extensive research in HF during the last decades, evidence for a relationship between patients' reported well-being and various objective measurements, such as heart rate (HR), has been scarce. Clear relationships are hard to find: signs can be identified without symptoms, and patients report different HQoL with similar objective measures of disease severity, as is well known in HF. 5 -7 The Systolic Heart failure treatment with the I f inhibitor ivabradine Trial (SHIFT) results showed that HR reduction with ivabradine in HF patients reduced cardiovascular mortality or hospital admissions for worsening HF. 8 In addition, there was an improvement in patient-reported global quality of life (P ¼ 0.0005) and in New York Heart Association (NYHA) class (P ¼ 0.001). Several drugs used to treat patients with HF can reduce HR, but their effects on symptoms are diverse and can be undesirable. 7 Health can be measured in objective and subjective dimensions. Whereas the objective dimension serves to define a patient's degree of the disease, the patient's subjective evaluation serves to translate that health status into the actual HQoL experienced. Thus, two patients with identical health status may have very different HQoL depending on their subjective experiences, expectations, and perceptions regarding health. 4 Thus, more detailed analyses using a validated HQoL instrument are needed to identify how HR reduction with ivabradine is related to variation in HQoL.
The aim of this SHIFT substudy was to assess the effect of ivabradine on HQoL and evaluate whether HQoL at baseline is associated with the risk of outcomes and whether changes in HR with ivabradine can translate into improved HQoL in parallel to reduced event rates in patients with chronic HF and systolic dysfunction.
Methods

Study design and patients
SHIFT was an event-driven, multinational, randomized, double-blind, placebo-controlled, parallel-group clinical trial in patients with moderate-to-severe HF and left ventricular systolic dysfunction. The design and results of the SHIFT study have been described previously. 8, 9 In brief, SHIFT evaluated 6505 patients with symptomatic chronic HF, left ventricular ejection fraction (LVEF) ≤35%, and in sinus rhythm with HR ≥ 70 bpm. They had been admitted to hospital for HF in the 12 months before randomization. The primary composite endpoint was cardiovascular death or hospital admission for worsening HF. The SHIFT population received background treatment maximized according to the guidelines for chronic HF. 1 Resting HR was measured by 12-lead electrocardiography in the supine position at baseline, 28 days after randomization (at the end of uptitration), and at study visits every 4 months. The starting dose was ivabradine 5 mg twice daily or matching placebo. The dose was adjusted throughout the study to 7.5, 5, or 2.5 mg twice daily, according to resting HR and tolerability. For the HQoL substudy, at participating centres after enrolment but prior to randomization, patients agreed to undergo periodic assessment as detailed below. They signed an additional informed consent permitting participation in this substudy.
Health-related quality of life questionnaire
Health-related quality of life was measured using the disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, at 4, 12, and 24 months of randomized treatment, and at last study visit. The KCCQ was developed to measure self-reported health status in patients with HF, and has been shown to be a valid, reliable, and responsive health status measure. 10 Centres that were included had access to the validated KCCQ in their respective language. The KCCQ is currently available in about 40 language versions and comprises 23 items, based on 5-, 6-, and 7-point Likert scales, including 8 dimension scores and 2 summary scores. For all dimension and summary scores, the higher the score, the better the patient's selfreported health status. The two KCCQ summary scores are presented in this report. Each ranges from 0 to 100: the overall summary score (OSS) is the mean of physical limitation, total symptom, quality of life, and social limitation scores; the clinical summary score (CSS) is the mean of the physical limitation and the total symptom domain scores. In order to avoid bias to healthier patients, particularly as differentially distributed deaths became increasingly apparent as the study progressed, for this report KCCQ analyses were focused to 12 months' follow-up and in surviving patients. However, differences at other assessment points are summarized for completeness. The primary relationship assessed in this substudy was that between baseline HQoL and outcomes. The placebo population was divided into three groups according to the baseline OSS or CSS score (low ,50, medium 50 -75, and high ≥75). The segregation points were selected on the basis of previous studies grouping patients into four categories, 3 but the two lowest categories (,25 and 25 -,50)
were combined in this study because relatively few patients fell into these groups. The three groups were analysed for the primary outcome of the main study and the secondary endpoints of all-cause death, cardiovascular death, death due to HF, all-cause hospital admission, and hospital admission for worsening HF. To explore the relationship between change in HQoL and change in HR, we divided the treatment groups by quintiles of HR reduction at 12 months and plotted these against the change in the KCCQ OSS and CSS over the same time period.
Statistical analyses
Statistical analyses were performed on patients randomized in the main study and participating in the HQoL substudy, who had taken at least one dose of study drug and had HQoL assessment both at baseline and follow-up. Baseline characteristics were presented using descriptive statistics with means (SD) for quantitative variables, and numbers and percentages for categorical variables. Baseline characteristics were compared across the classes of baseline OSS (low ,50, medium 50-75, high ≥75) using a Kruskal-Wallis test for continuous variables and a x 2 test for categorical variables.
The relationship between baseline KCCQ scores and the primary composite endpoint, as well as its components and the secondary endpoints, was investigated in patients allocated to placebo. Hazard ratios comparing patients with lower scores to patients with the best scores as referent were estimated using Cox proportional hazards models adjusted for the following parameters at baseline: betablocker intake at randomization, NYHA class, LVEF, aetiology of HF (ischaemic or not), age, systolic blood pressure, HR, and creatinine clearance (a fully adjusted model was performed and produced similar results). The associated 95% confidence intervals (CIs) and P-values were also provided. Time-to-event curves for each KCCQ classes were estimated using the Kaplan -Meier method.
The treatment effect on the change from baseline in KCCQ scores at 12 months was assessed, using a covariance analysis adjusted for baseline KCCQ, beta-blocker intake at randomization and country. The differences between treatment groups were estimated using adjusted least square means from these models, with two-sided 95% CIs and P-values.
The relationship between change in KCCQ scores and change in HR at 12 months was investigated in each treatment group. The mean I. Ekman et al. HR reduction with ivabradine and health related quality of life change in KCCQ scores was calculated in each quintile of change in HR at 12 months, for ivabradine and placebo groups separately.
The correlation between changes in KCCQ and HR was tested using a regression linear model including the two treatment groups.
SAS (version 9.1) was used for all analyses.
Results
In this substudy, 1944 patients were evaluated from 24 countries (968 ivabradine, 976 placebo) with a median follow-up of 24.5 months (maximum 29.3 months) ( Figure 1 Table 1 shows the baseline characteristics of the population with KCCQ evaluation. The mean age of the patients was 60.7 (SD 11.3) years and 1478 (76%) were male. More patients were in NYHA class II (58%) than class III/IV (42%), with a mean LVEF of 28.3% (SD 5.4%) and HR of 79.8 (SD 9.0) bpm. Most of the patients were receiving recommended HF therapy, including angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers (95%) and a beta-blocker (90%). Compared with the main study, more patients were in NYHA class II, but there were no other important differences between the KCCQ population and the population in the main study (data not shown).
Mean score at baseline for OSS was 64.8 (SD 19.9) and CSS 68.4 (SD 20.3). The baseline characteristics of the KCCQ population divided into three classes according to the OSS at baseline are presented in Table 2 . As would be expected, the patients with higher OSS scores at baseline, i.e. better HQoL, had shorter duration of HF and a milder NYHA class. Patients in the higher OSS group also had lower HR and were less likely to have a history of myocardial infarction, hypertension, diabetes, and stroke.
Death or hospital admission increased as baseline KCCQ scores decreased (Table 3, Figure 2 ). Patients with KCCQ , 50 for each score had a significantly higher risk for the primary composite outcome (CSS, P ¼ 0.002; OSS, P ¼ 0.007) compared with patients in the CSS and OSS groups scoring ≥75. They were also at higher risk for all-cause hospital admission (OSS, hazard ratio 1.54, 95% CI 1.18-2.00, P ¼ 0.002; CSS, hazard ratio 1.57, 95% CI 1.20-2.04, P , 0.001) and hospital admission for worsening HF (OSS, hazard ratio 1.60, 95% CI 1.10-2.33, P ¼ 0.014; CSS, hazard ratio 1.72, 95% CI 1.18-2.49, P ¼ 0.005). The CSS scores were consistently more predictive than the OSS. Table 4 shows that treatment with ivabradine reduced mean HR in the KCCQ population at 12 months by 14. Table S1 ). Figure 3 shows the percentage distribution by study group divided by changes of 5-point score improvement or decline after 12 months. At 12 months, HQoL (both CSS and OSS) was better preserved in the ivabradine group compared with placebo. These changes were consistent across all eight dimensions (Supplementary material online, Table S1 ). Figure 4 shows that these changes were associated with the changes in HR for both CSS (P , 0.001) and OSS (P , 0.001). The relationship was found in both allocation groups, though the improvements in CSS and OSS were greater in those patients with the greatest reduction in HR and this was more marked in the ivabradine group. Similarly to the overall SHIFT population, at last post-baseline visit 29.0% of ivabradine patients improved in NYHA class vs. 24.2% in the placebo group (P ¼ 0.0156), and patient-reported global assessment improved in 65.9% of ivabradine patients vs. 61.3% in placebo (P ¼ 0.0345).
Discussion
In this prespecified prospective SHIFT substudy, in patients with systolic HF, HR was associated with HQoL. More importantly, the reduction in HR due to ivabradine was associated with increases in HQoL, paralleling the reduction in primary outcome events. This is, to our knowledge, the first report showing not only that resting HR is inversely related to the magnitude of HQoL, but also that the change in HR is related to the change in HQoL at 12 months, and that this benefit is maintained over a longer interval (last post-baseline visit). As treatment with ivabradine was associated with a placebo-corrected 10 bpm reduction in HR after 12 months, more patients improved HQoL compared with placebo. Qualitatively, similar benefits were found with ivabradine vs. Hazard ratios calculated by adjustment for beta-blocker intake at randomization, left ventricular ejection fraction, age, systolic blood pressure, heart rate, New York Heart Association Class, estimated glomerular filtration rate, and non-ischaemic cause of heart failure. CI ¼ confidence interval. a Number of patients per class OSS: 340 patients ≥75, 410 patients 50 to ,75, 226 patients ,50. Figure 3 The percentage distribution by study group divided by changes of Kansas City Cardiomyopathy Questionnaire (KCCQ), 5-point score improvement or decline after 12 months, for clinical summary score (CSS) (A). Net proportion with 5-unit advantage if assigned to ivabradine rather than placebo ¼ 7.8% and overall summary score (OSS) (B). Net proportion with 5-unit advantage if assigned to ivabradine rather than placebo ¼ 8.2%. Net proportion with 5-unit advantage is calculated by adding the differences in the proportion that declined or improved by at least 5 units on ivabradine compared with placebo.
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placebo at 4 months and last post-baseline visit, though results at the later assessment points are potentially confounded by differential death rates between ivabradine and placebo groups. Furthermore, at baseline, worse HQoL, i.e. a lower KCCQ score, was associated with increased risk of cardiovascular death or hospital admission for worsening HF (primary composite endpoint). Interestingly, the CSS scores appeared to be more predictive for all six subgroups of outcomes. As the CSS part of KCCQ specifically reflects symptoms, this observation supports the prognostic importance of symptom perception (the subjective component of the disease) by the patients on major adverse cardiac events.
These findings are consistent with the benefits of HR reduction with ivabradine in HF patients, as demonstrated in the primary SHIFT analysis, which revealed the beneficial role of HR reduction in adverse clinical outcomes associated with HF. 8 SHIFT also found significant improvements in the NYHA class and patient-reported global assessment. 8 The present analyses suggest that the ivabradine-associated reduction in the severity of HF, as reflected by reduced hospital admissions and improved NYHA functional class, also translates into a favourable impact on HQoL. In contrast, treatment with beta-blockers, associated with similar HR reduction and also reducing HF mortality, has not resulted in improved HQoL, as reported in a meta-analysis by Dobre et al.
7
Chronic HF is associated with relatively high morbidity and mortality. Therefore, interventions have focused primarily on assessments of mortality and hospital admissions as measures of important benefit. Reduction in mortality is important in chronic HF, but mortality is a poor reflection of how patients with HF experience their situation and what impact a treatment may have on a patient's day-to-day life. For patients, quality of life (e.g. symptoms and the impact of their illness on social, emotional and occupational functioning) may be as important as longevity, 11 since HF affects patients' quality of life more than many other chronic diseases. 12 In addition, there is a relationship between worsening symptoms and quality of life with increased mortality and hospital admissions. 13 -15 Clearly, symptoms and well-being as reported by patients are not only important targets for therapy in their own right but our findings, together with previous experience, indicate that improved HQoL can also be reflected in improved survival. 13 -15 The overall aim in care for patients is relief of symptoms and several drug interventions can improve symptoms but do not affect (or adversely affect) mortality, e.g. inotropes. Patient reported Figure 4 Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ) at 12 months plotted against changes in heart rate for overall summary score (OSS) (P , 0.001) (A) and clinical summary score CSS (P , 0.001) (B).
outcomes are important for the interpretation and understanding of patients with CHF since they reflect either the disease itself or the patient's perception of the illness. Our findings confirm and extend previous findings with KCCQ in a larger population.
Health-related quality of life is recognized as an important target of therapy for patients with chronic HF by the European Medicines Agency, 16 as well as the US Food and Drug Administration. 17 Our findings suggest that lowering HR with ivabradine achieves reduction of major morbidity and mortality, as well as improvements in HQoL. Moreover, the improvement in KCCQ scores on ivabradine compared with baseline pre-ivabradine of at least 5 points ( Table 4 , Figure 3 ) is considered to be clinically meaningful. 18 The difference in score between ivabradine and placebo was not of the same magnitude as the within group comparison. The changes at 12 months were consistent across all eight dimensions (Supplementary material online, Table S1 ). The size of change in HQoL is inevitably smaller than that of a more direct or more objective marker of the disease, and the broader the concept is (such as HQoL), the smaller will be the change. This is particularly true in this context, even if the KCCQ is specific to the condition, it is well-known that the correlation between HQoL and markers of chronic heart failure is not high (that is why patient reported outcome brings additional information that is not covered by other endpoints).
There are several limitations in our analysis. First, HQoL is a subjective experience that differs between individuals and is therefore difficult to measure on a group level. We used KCCQ, a validated instrument in HF, which has shown greater sensitivity for individual changes over time when compared with other disease-specific instruments, such as the Minnesota Living with Heart Failure questionnaire (MLHFQ). 10, 19 The KCCQ has also shown acceptable cross-sectional validity, reliability, and responsiveness in patients with chronic HF. 20 Another limitation is that patients included in SHIFT were relatively young and selected by design to be in sinus rhythm and have HR ≥ 70 bpm and a previous hospital admission, factors which might impact on HQoL. Finally, 58% of subjects who participated in this substudy were in NYHA II compared with 49% in the overall population. This fact may impact on the extent to which our results can be extrapolated quantitatively to a population comprising predominantly NYHA functional class III/IV patients, but should not alter the central tendency of our results in such a population.
Conclusions
In patients with systolic HF and HR ≥ 70 bpm in sinus rhythm, HR is related to HQoL and the magnitude of HR reduction with ivabradine is related to the degree of improvement in HQoL.
Health-related quality of life score, assessed by the disease-specific KCCQ, is inversely associated with the risk of cardiovascular death or hospital admission for HF.
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